{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036905","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2026-08-10T21:07:05+00:00","discovered_at":"2026-08-10T21:08:02.435122+00:00","generated_at":"2026-08-10T21:08:15.755854+00:00","sec_items":["7.01","2.02","9.01"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Elite Pharmaceuticals to release Q1 FY2027 results Aug 13; earnings call Aug 14","bullets":["Q1 FY2027 (ended June 30, 2026) financial results to be released Thursday, August 13, 2026.","Conference call Friday, August 14, 2026, 11:30 AM EDT; dial-in 1-800-346-7359 (domestic) or 1-973-528-0008 (international).","Conference number 98840; general questions due Aug 12, financial questions due Aug 13 via dianne@elitepharma.com.","Call to cover financial/operating results and provide a general business update; audio replay available at elite.irpass.com.","Company develops and distributes niche generic oral controlled-release products from Northvale, NJ facility."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036905","json":"https://secwatch.observer/filing/0001493152-26-036905.json","markdown":"https://secwatch.observer/filing/0001493152-26-036905.md","text":"https://secwatch.observer/filing/0001493152-26-036905.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226036905/0001493152-26-036905-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315226036905/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T21:08:15.755854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}